U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07793968) titled 'Point of Care NT-proBNP Testing for Suspected New Heart Failure Acute Care' on March 13.
Brief Summary: Heart failure is a serious condition that can be difficult to diagnose quickly when patients present to hospital with symptoms such as breathlessness. Delays in diagnosis may delay treatment and adversely affect patient outcomes. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a blood biomarker recommended in national and international guidelines to support the diagnosis of heart failure. Conventional laboratory testing can take several hours before results are available.
This study will evaluate the use of point-of-care...